Department of Allergy/Immunology/Immunizations, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Hum Vaccin Immunother. 2012 May;8(5):582-6. doi: 10.4161/hv.19517. Epub 2012 May 1.
A 20-y-old male presented with symptoms of meningococcal sepsis and died despite appropriate medical interventions. Blood cultures grew N. meningitidis serogroup Y. The patient had received the meningococcal quadrivalent (A,C,W-135,Y) polysaccharide vaccine 15 mo previously. Because the patient had a history of meningococcal meningitis at age 10, archived serum was obtained for further analysis. Complement component C7 was found to be deficient, and antibody levels to meningococcal polysaccharides were undetectable for two serogroups and low for the infecting serogroup 10 mo post-vaccination. This case highlights the fact that some individuals with terminal complement component deficiencies mount an impaired or short-lived response to vaccination with meningococcal capsular polysaccharides, and underscores the appropriateness of a more aggressive vaccination strategy in this patient population.
一名 20 岁男性出现脑膜炎奈瑟菌败血症症状,尽管进行了适当的医疗干预,仍不幸死亡。血培养出脑膜炎奈瑟菌血清群 Y。该患者在 15 个月前接种了脑膜炎球菌四价(A、C、W-135、Y)多糖疫苗。由于该患者在 10 岁时曾患有脑膜炎奈瑟菌脑膜炎,因此获得了存档的血清进行进一步分析。发现补体成分 C7 缺乏,接种疫苗 10 个月后,两种血清群的脑膜炎球菌多糖抗体水平无法检测到,而感染血清群的抗体水平较低。本病例强调了这样一个事实,即一些末端补体成分缺陷的个体对脑膜炎球菌荚膜多糖疫苗接种的反应受损或短暂,这突出了在该患者人群中采取更积极的疫苗接种策略的适当性。